The Munich Adrenaline Cancer Study
Launched by TECHNICAL UNIVERSITY OF MUNICH · Apr 12, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Exercise is generally recommended as an adjunct therapy for adult cancer patients as it counteracts the adverse effects of cancer and its treatment. According to epidemiological data, exercise is also associated with a reduced risk of tumour developement and an improval of survival in some tumours. However, the underlying mechanisms by which exercise affects tumour cells are poorly understood in adult cancer patients and mostly unknown in children. Recent studies demonstrate anti-cancer effects of exercise-induced adrenaline through natural killer cell mobilisation and Hippo signalling. In ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • newly diagnosed pediatric cancer or relapse
- • aged 6-18 years
- • between the first and third cycle of chemotherapy
- • diagnosis and treatment at the Kinderklinik München Schwabing, Department of Paediatrics and Children's Cancer Research Centre, Technical University of Munich
- • German language
- • informed consent as documented by signature
- Exclusion Criteria:
- • Any medical contraindication with respect to a high-intensity interval exercise intervention (e.g., cardiovascular complications, comorbidities, bleeding risk, pain, infection, nausea, orthopedic impairment of the lower extremities)
- • inability to follow the procedures and understand the intervention and assessment of the study, e.g., due to cognitive impairment, language problems, psychological disorders etc.
About Technical University Of Munich
The Technical University of Munich (TUM) is a leading research institution in Germany, renowned for its commitment to excellence in education, innovation, and technology transfer. With a strong emphasis on interdisciplinary collaboration, TUM fosters advancements in various fields, including medicine and life sciences. The university actively engages in clinical research, aiming to translate scientific discoveries into practical applications that improve patient outcomes. Through its state-of-the-art facilities and a network of partnerships with hospitals and industry, TUM is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards and contribute significantly to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Trial Officials
Irene Teichert-von Lüttichau, PD Dr. med.
Principal Investigator
TUM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials